Article Text

Download PDFPDF

Original article
Defining patient centricity with patients for patients and caregivers: a collaborative endeavour
  1. Guy Yeoman1,
  2. Patricia Furlong2,
  3. Michael Seres3,
  4. Helena Binder4,
  5. Helena Chung5,
  6. Vincenzo Garzya1,
  7. Rachel RM Jones6
  1. 1AstraZeneca Pharmaceuticals, Melbourn, UK
  2. 2Patient Project Muscular Dystrophy, Hackensack, New Jersey, USA
  3. 311Health, Borehamwood, Hertfordshire, UK
  4. 4Corvista, Cheshire, UK
  5. 5AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA
  6. 6Formerly AstraZeneca Pharmaceuticals, Macclesfield, UK
  1. Correspondence to Guy Yeoman, AstraZeneca Pharmaceuticals, Da Vinci Building, Melbourn Science Park, Melbourn, Royston, SJ8 6HB UK; Guy.Yeoman{at}


Background Patient engagement is an essential aspect in the research/development of biopharmaceutical products and disease management. Improving the lives of patients requires a deep understanding of their medical conditions, experiences, needs and priorities. However, a consistent definition of patient centricity is lacking. A series of initiatives was conducted to define patient centricity and its important principles impacting the biopharmaceutical industry.

Methods Interviews, questionnaires and literature reviews were conducted involving key stakeholders to initially identify issues of importance to patients, healthcare providers and payers. Subsequently, two identical workshops which included 22 patients/carers created a definition of patient centricity and the healthcare values important to patients/caregivers. Outputs were tested in a validation exercise involving patients in predominantly US (n=470) and European (n=703) patient forums.

Results Initial research provided deeper understanding of patient needs and key topics of interest that were used to cocreate a definition of patient centricity and 10 associated principles of importance to the biopharmaceutical industry. Wider testing of these outputs among predominantly US/European patient communities confirmed their validity. Patient centricity should be defined as ‘Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family’. Important principles for patients focused on education/information, cocreation, access and transparency.

Conclusions The development of a consistent definition of patient centricity and its associated principles provides an opportunity for biopharmaceutical companies to adopt and use these as a reference point for consistent patient engagement throughout the product life cycle.

  • patient centricity
  • patient engagement
  • pharmaceutical development
  • health care management

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors contributed to design, collection of data or interpretation of the results reported herein, and all authors contributed to the drafting, review and approval of the manuscript prior to submission.

  • Funding AstraZeneca.

  • Competing interests GY, HC and VG are employees of AstraZeneca. RRMJ is an ex-employee of AstraZeneca.

  • Provenance and peer review Not commissioned; externally peer reviewed.